29 Mar 2016
The Central Drugs Standard Control Organization is starting a series of surprise checks at various drug manufacturing units throughout the country next month onwards. The inspection exercise is being undertaken in the face of innumerable complaints coming in from the US Food and Drug Administration(FDA) about faults in the manufacturing plants leading to manufacture of sub standard medicines.
Following the inspection pattern of the US FDA, the CDSCO is planning to undertake aggressive surveillance that would help weed out units that happen to be deviating from the standard manufacturing practices , thereby, compromising on patient safety. This move comes amidst growing concern about the deteriorating quality standards of medicines in the market. The CDSCO’s aim through these surprise checks is to ensure that sub standard medicines do not gain entry into the consumer market.